Skip to main navigation Skip to search Skip to main content

A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab (GO) to CPX-351 with GO, and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3

Upstate Medical University

Project: Research

Project Details

StatusActive
Effective start/end date03/1/22 → 02/28/27

Funding

  • Public Health Institute: $5,000.00